NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

Rhea-AI Summary

NeuroMetrix, Inc. (Nasdaq: NURO) has launched a marketing initiative targeting chronic knee pain, utilizing direct-to-consumer digital marketing and outreach to healthcare providers. Approximately 25% of U.S. adults experience frequent knee pain, often treated with medications that can have serious side effects. Quell, a wearable TENS device, offers a non-invasive solution tailored for knee pain alleviation. The device has specific FDA clearance for nighttime use and tracks health metrics through a mobile app. Since its OTC availability in 2015, Quell 2.0 remains a frontrunner in TENS technology.

Positive

• Launch of targeted marketing initiative for chronic knee pain, potentially expanding customer base.
• Quell device offers a non-invasive and safe alternative to traditional pain medications.
• FDA clearance for use while sleeping enhances Quell's usability.
• Strong consumer interest with 40% of users wearing the device overnight.

Negative

• Chronic knee pain treatment market is competitive, with established options like surgery and opioids.
• Market penetration may be limited due to reliance on digital marketing.

WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers about the use of Quell for their patients with knee pain.

About one-quarter of U.S. adults suffer from frequent knee pain, which limits function, decreases mobility, impacts sleep and reduces quality of life.  Chronic knee pain is typically treated with oral non-steroidal anti-inflammatory drugs and occasionally prescription opioids. These medications have side effects and, in the case of opioids, may lead to addiction.  Surgery is an effective option for some individuals with chronic knee pain.

Transcutaneous electrical nerve stimulation (TENS) is a safe, non-invasive pain relief option, that has been used by physicians, physical therapists, and other health care professions for decades to treat chronic pain.  Quell is the only true wearable TENS device.  It is well suited to chronic knee pain because it is worn just below the knee, is not much larger than a credit card, and is comfortable enough to use 24/7.  Quell is the only TENS device with specific FDA 510(k) clearance for use while sleeping.  According to the Company’s Quell Health Cloud^™, regular Quell users with knee pain wear their device for 10 hours a day and 40% use it while sleeping.  

Quell has been commercially available over-the-counter since 2015.  The most recent version, Quell 2.0, was launched in late 2018 and represents the most advanced TENS technology on the market.  Key features include:

• Only TENS device powered by a proprietary neurostimulation microchip
• Prescription strength nerve stimulation
• Therapy Autopilot^™ automatically controls and personalizes nerve stimulation
• Advanced power management requires battery recharging only once or twice a week
• Controlled and enhanced by the industry leading Quell Relief mobile app
• Detects and compensates for changes in the weather that may aggravate pain
• Digital health enabled – objectively tracks sleep, activity and gait and user reported pain
• Covered by 14 U.S. patents

Quell is available to consumers at QuellRelief.com.  Veterans may obtain Quell through their VA hospital (contact customercare@quellrelief.com for information).

About NeuroMetrix

NeuroMetrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices that are used throughout the world. The Company has three FDA cleared commercial products. DPNCheck^® is a point-of-care test that is used to evaluate peripheral neuropathies. ADVANCE^™ is a point-of-care device that provides nerve conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. Quell^® 2.0 is a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain and is available over-the-counter. The Company maintains an active, industry-leading R&D program. For more information, visit NeuroMetrix.com.

NeuroMetrix, Inc.

Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ae1bfdb-f6bd-43e6-8cea-696c3925150d

FAQ

What new marketing strategy did NeuroMetrix announce for NURO on June 10, 2020?

NeuroMetrix announced a marketing initiative focusing on chronic knee pain through direct-to-consumer digital marketing and outreach to healthcare providers.

What device is NeuroMetrix promoting for chronic knee pain?

NeuroMetrix is promoting Quell, a wearable TENS device designed specifically for chronic knee pain relief.

What percentage of U.S. adults suffer from frequent knee pain according to the NeuroMetrix press release?

According to the press release, approximately one-quarter (25%) of U.S. adults suffer from frequent knee pain.

How does Quell differ from other treatments for knee pain?

Quell offers a non-invasive, wearable TENS treatment, unlike traditional methods that can have serious side effects.

What are the specific FDA clearances for the Quell device?

The Quell device has FDA 510(k) clearance specifically for use while sleeping, making it unique in its category.